AmerisourceBergen Completes Acquisition of Minority Interest in Profarma Distribuidora de Produtos Farmacêuticos S.A.

  AmerisourceBergen Completes Acquisition of Minority Interest in Profarma
  Distribuidora de Produtos Farmacêuticos S.A.

Expands Global Footprint and Launches Joint Venture for Specialty Distribution
                                  in Brazil

Business Wire

VALLEY FORGE, Pa. -- June 26, 2014

AmerisourceBergen Corporation (NYSE: ABC) today announced that it has
completed the acquisition of a minority stake in Profarma Distribuidora de
Produtos Farmacêuticos S.A. (Profarma), a leading pharmaceutical wholesaler in
Brazil. In addition, AmerisourceBergen and Profarma have launched a joint
venture to provide enhanced specialty distribution and services to the
Brazilian marketplace. The Company has invested a total of approximately $110
million in an approximately 19.9% minority stake in Profarma, and a 50% stake
in the specialty joint venture. AmerisourceBergen does not expect the
transaction to have a meaningful impact to its adjusted earnings per share
from continuing operations for fiscal 2014.

“With Profarma’s long history of success and AmerisourceBergen’s extensive
expertise in specialty distribution, I am very excited about the potential
this unique combination brings to the Brazilian market,” said Steven H.
Collis, AmerisourceBergen President and Chief Executive Officer. “This
represents a tremendous opportunity to expand our international presence,
introduce new products and services into a fast-growing market, and enhance
future growth for both companies.”

Profarma believes that it has taken two important steps with the capital
increase and the creation of the joint venture. “We feel proud of and
motivated by the association with AmerisourceBergen. We believe both companies
will benefit from sharing knowledge and experience. In addition, the capital
increase gives us the strength we need to forge ahead with our growth
strategy,” said Sammy Birmacker, Profarma’s CEO.

The specialty joint venture will be led by Craig Miller, who will serve as the
chief executive officer of the specialty joint venture, and who previously led
AmerisourceBergen’s US BioServices. “I am looking forward to helping shape
healthcare delivery in Brazil through our knowledge, reach and partnership
with Profarma, and to the benefit of our manufacturer and healthcare provider
customers worldwide,” said Miller.

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing and
distribution services companies, helping both healthcare providers and
pharmaceutical and biotech manufacturers improve patient access to products
and enhance patient care. With services ranging from drug distribution and
niche premium logistics to reimbursement and pharmaceutical consulting
services, AmerisourceBergen delivers innovative programs and solutions across
the pharmaceutical supply channel. With over $100 billion in annualized
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs
approximately 13,000 people. AmerisourceBergen is ranked #28 on the Fortune
500 list. For more information, go to www.amerisourcebergen.com.

About Profarma Distribuidora de Produtos Farmacêuticos S.A.

Profarma Distribuidora de Produtos Farmacêuticos S.A. has been engaged for 52
years in the distribution of pharmaceuticals, personal care products and
cosmetics in Brazil's most populous states. In 2013, with the acquisition of
the retail chains Drogasmil/Farmalife and Tamoio, it became one of the largest
mixed distributors in Latin America and the largest in Brazil. With 12
Distribution Centers, Profarma markets approximately 18.0 million units per
month and serves around 33,000 sales outlets. In the pharmaceutical retail
market, it is the tenth largest chain in Brazil, with 140 stores in Rio de
Janeiro. Covering a geographic area that corresponds to 93.5% of the consumer
market for pharmaceutical products in Brazil, Profarma with its specialized
and committed team, aims to be Brazil's largest and most profitable mixed
distributor of pharmaceutical products by delivering consistent and
sustainable results, maintaining low operating costs, strengthening its
competitive advantages and maximizing value for its stockholders. For more
information, go to www.Profarma.com.br.

AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this news release are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Words such as
“expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,”
“will,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy,” “on
track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,”
“assume,” variations of such words, and similar expressions are intended to
identify such forward-looking statements. These statements are based on
management’s current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance and
are based on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors that could
cause actual results to differ materially from those projected, anticipated,
or implied are the following: changes in pharmaceutical market growth rates;
the loss of one or more key customer or supplier relationships; the retention
of key customer or supplier relationships under less favorable economics;
changes in customer mix; customer delinquencies, defaults or insolvencies;
supplier defaults or insolvencies; changes in branded and/or generic
pharmaceutical manufacturers’ pricing and distribution policies or practices;
adverse resolution of any contract or other dispute with customers or
suppliers; federal and state government enforcement initiatives to detect and
prevent suspicious orders of controlled substances and the diversion of
controlled substances, federal and state prosecution of alleged violations of
related laws and regulations, and any related litigation, including
shareholder derivative lawsuits or other disputes relating to
AmerisourceBergen’s distribution of controlled substances; qui tam litigation
for alleged violations of fraud and abuse laws and regulations and/or any
other laws and regulations governing the marketing, sale, purchase and/or
dispensing of pharmaceutical products or services and any related litigation,
including shareholder derivative lawsuits; changes in federal and state
legislation or regulatory action affecting pharmaceutical product pricing or
reimbursement policies, including under Medicaid and Medicare, and the effect
of such changes on AmerisourceBergen’s customers; changes in regulatory or
clinical medical guidelines and/or labeling for the pharmaceutical products we
distribute; price inflation in branded and generic pharmaceuticals and price
deflation in generics; greater or less than anticipated benefit from launches
of the generic versions of previously patented pharmaceutical products;
significant breakdown or interruption of AmerisourceBergen’s information
technology systems; AmerisourceBergen’s inability to realize the anticipated
benefits of the implementation of an enterprise resource planning (ERP)
system; interest rate and foreign currency exchange rate fluctuations; risks
associated with international business operations, including non-compliance
with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic
sanctions and import laws and regulations; economic, business, competitive
and/or regulatory developments in countries where we do business and/or
operate outside of the United States; risks associated with the strategic,
long-term relationship among Walgreen Co., Alliance Boots GmbH, and
AmerisourceBergen, the occurrence of any event, change or other circumstance
that could give rise to the termination, cross-termination or modification of
any of the transaction documents among the parties (including, among others,
the distribution agreement or the generics agreement), an impact on
AmerisourceBergen’s earnings per share resulting from the issuance of the
warrants to subsidiaries of Walgreen Co. and Alliance Boots GmbH (the
“Warrants”), an inability to realize anticipated benefits (including benefits
resulting from participation in the Walgreens Boots Alliance Development GmbH
joint venture), the disruption of AmerisourceBergen’s cash flow and ability to
return value to its stockholders in accordance with its past practices,
disruption of or changes in vendor, payer and customer relationships and
terms, and the reduction of AmerisourceBergen’s operational, strategic or
financial flexibility; the acquisition of businesses that do not perform as we
expect or that are difficult for us to integrate or control;
AmerisourceBergen’s inability to implement its hedging strategy to mitigate
the potentially dilutive effect of the issuance of shares of its common stock
upon exercise of the Warrants, including its inability to repurchase shares of
its common stock under its new share repurchase program due to its financial
performance, the current and future share price of its common stock, its
expected cash flows, competing priorities for capital, and overall market
conditions; AmerisourceBergen’s inability to successfully complete any other
transaction that we may wish to pursue from time to time; changes in tax laws
or legislative initiatives that could adversely affect AmerisourceBergen’s tax
positions and/or AmerisourceBergen’s tax liabilities or adverse resolution of
challenges to AmerisourceBergen’s tax positions; increased costs of
maintaining, or reductions in AmerisourceBergen’s ability to maintain,
adequate liquidity and financing sources; volatility and deterioration of the
capital and credit markets; natural disasters or other unexpected events that
affect AmerisourceBergen’s operations; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting
AmerisourceBergen’s business generally. Certain additional factors that
management believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are set forth
(i) in Item 1A (Risk Factors) and Item 1 (Business) in the Company’s Annual
Report on Form 10-K for the fiscal year ended September 30, 2013 and elsewhere
in that report and (ii) in other reports.

Contact:

AmerisourceBergen Corporation
Barbara Brungess
Vice President, Corporate & Investor Relations
610-727-7199
bbrungess@amerisourcebergen.com
 
Press spacebar to pause and continue. Press esc to stop.